{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:19:38Z","timestamp":1795126778618,"version":"4.10.3"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.semarthrit.2022.151979","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T11:21:42Z","timestamp":1644405702000},"page":"151979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"special_numbering":"C","title":["Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries"],"prefix":"10.1016","volume":"53","author":[{"given":"Alexander","family":"Egeberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana Aviaaja Lippert","family":"Rosen\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Thein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Hillo","family":"L\u00f8rup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia-Louise","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Nymand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Erik","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Francis","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene Lindholm","family":"Cordtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-3280","authenticated-orcid":false,"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Erik","family":"Bryld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Kirchheiner","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pil","family":"H\u00f8jgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.semarthrit.2022.151979_bib0001","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/jid.2015.206","article-title":"Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: a Systematic Review and Meta-Analysis","volume":"135","author":"Nast","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151979_bib0002","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/09546634.2013.826341","article-title":"Biologic fatigue in psoriasis","volume":"25","author":"Levin","year":"2014","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151979_bib0003","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjd.13343","article-title":"Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris","volume":"172","author":"Gniadecki","year":"2015","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151979_bib0004","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.13611","article-title":"Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"30","author":"Menter","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151979_bib0005","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: a Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151979_bib0006","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/jdv.12492","article-title":"Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry","volume":"29","author":"Carretero","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151979_bib0007","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/annrheumdis-2019-215427","article-title":"Treatment response and drug retention rates in 24 195 biologic-naive patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration","volume":"78","author":"Ornbjerg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151979_bib0008","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/art.41031","article-title":"Comparative Effectiveness of Certolizumab Pegol, Abatacept, and Biosimilar Infliximab in Patients With Rheumatoid Arthritis Treated in Routine Care: observational Data From the Danish DANBIO Registry Emulating a Randomized Trial","volume":"71","author":"Gron","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151979_bib0009","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","article-title":"The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries","volume":"55","author":"Hojgaard","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2022.151979_bib0010","article-title":"Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis","author":"Lindstrom","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2022.151979_bib0011","article-title":"One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in Spondyloarthritis","author":"Glintborg","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151979_bib0012","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials","volume":"148","author":"Garcia-Doval","year":"2012","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151979_bib0013","first-page":"725","article-title":"Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice","volume":"56","author":"Aaltonen","year":"2017","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151979_bib0014","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1002\/art.22193","article-title":"Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials","volume":"54","author":"Zink","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151979_bib0015","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2022.151979_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2019.03.048","article-title":"Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis","author":"Egeberg","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151979_bib0017","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1365-2133.2011.10213.x","article-title":"Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris","volume":"164","author":"Gniadecki","year":"2011","journal-title":"Br J Dermatol"},{"issue":"9596","key":"10.1016\/j.semarthrit.2022.151979_bib0018","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151979_bib0019","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","article-title":"Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: a Systematic Review and Meta-Analysis","volume":"95","author":"Wang","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151979_bib0020","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151979_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001363","article-title":"How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers","volume":"6","author":"Chatzidionysiou","year":"2020","journal-title":"RMD Open"},{"issue":"16","key":"10.1016\/j.semarthrit.2022.151979_bib0022","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151979_bib0023","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","article-title":"Drug Survival of IL-12\/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: a Retrospective Multi-Country, Multicentric Cohort Study","volume":"22","author":"Torres","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151979_bib0024","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jamadermatol.2020.4202","article-title":"Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: a Study From the British Association of Dermatologists Biologics and Immunomodulators Register","volume":"157","author":"Yiu","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151979_bib0025","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jamadermatol.2018.0183","article-title":"Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR","volume":"154","author":"Mason","year":"2018","journal-title":"JAMA Dermatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:08:15Z","timestamp":1758733695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":25,"alternative-id":["S0049017222000300"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151979","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151979"}}